In IDH-wildtype tumors with retained ATRX, the presence of necrosis and/or MVP or TERT mutation, EGFR amplification and/or +7/−10, and H3.3G34 wildtype status warrant the classification as GBM. The gene discussed is IDH2; the disease is glioblastoma.